Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis

European Journal of Dermatology

Volumn 13, Issue 5, 2003, Pages 455-461

  Bos, Jan D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atopy; Dermatitis; Eczema; Glucocorticoids; Pimecrolimus; Tacrolimus

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; FK 506 BINDING PROTEIN; HYDROCORTISONE ACETATE; IMMUNOMODULATING AGENT; MESSENGER RNA; PIMECROLIMUS; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREAM; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; EXPERIMENTAL MOUSE; HUMAN; LONG TERM CARE; MOLECULAR SIZE; NONHUMAN; OINTMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN ABSORPTION; SKIN BURNING SENSATION; SKIN PERMEABILITY; SKIN TINGLING; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN; TACROLIMUS; TREATMENT OUTCOME;

EID: 0142246451     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Bos JD, Kapsenberg ML, Sillevis Smitt JH. Pathogenesis of atopic eczema. Lancet 1994; 343: 1338-41.
2. Johansson SGO, O'B Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
3. Bos JD. Atopiform dermatitis. Br J Dermatol 2002; 147: 426-9.
4. Schmid Grendelmeier P, Simon D, Simon H-U, Akdis CA, Wüthrich B. Epidemiology, clinical feotures, and immunology of the « intrinsic » (non-IgE-mediated) type of otopic dermatitis (contitutional dermatitis). Allergy 2001; 56: 841-9.
5. Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S, et al. Role of T cells and cytokines in the intrinsic form of atopic dermotitis. Curr Probl Dermatol 1999; 28: 37-44.
6. Bos JD, van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of atopic dermotitis. Exp Dermatol 1998; 7: 132-8.
7. Williams HC, Wüthrich B. The natural history of atopic dermotitis. In: Williams HC, editor. Atopic dermotitis. The epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press, 2000. p. 41-59.
8. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998; 94: 557-72.
9. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002; 71: 9-15.
10. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997; 15: 715-21
11. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinicol pharmacology and therapeutic use. Am J Clin Dermatol 2002; 3: 47-58.
12. Goerz G, Lehmann P. Topical treatment with corticosteroids. In: Ruzicka T, Ring J, Przybilla B, editors. Handbook of atopic eczema; 1991. p. 375-390.
13. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35: 615-9.
14. Vivier A du, Stoughton AB. Acute tolerance to effects of topical glucocorticosteroids. Br J Dermatol 1976; 94 suppl12: 25-32.
15. Singh G, Singh PK. Tachyphylaxis to topical steroids measured by histamine-induced wheal suppression. Int J Dermatol 1986; 25: 324-6.
16. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979; 18: 23-31.
17. Zheng PS, Lavker RM, Lehmann P, Kligman AM. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol 1984; 82: 345-52.
18. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6.
19. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41.
20. Bos JD, van Leent EJM. Tacrolimus (FK506): topical inflammatory cytokine inhibitor. J Cutan Med Surg 2001; 5 (Suppl. 3): 7-11.
21. Winiski A, Wang S, Schwendinger B, Stuetz A. Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T cell line (Jurkat) measured via RT-PCR and ELISA. J Invest Dermatol 2002; 119: 347.
22. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, et al. For the European Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547-55.
23. Reitamo S, van Leent EJM, Ho V, Harper J, Ruzicka T, Kalimo K, et al. For the European/Canadian Tacrolimus Ointment Study Group. Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermotitis. J Allergy Clin Immunol 2002; 109: 539-46.
24. Reitamo S, Ortonne JP, Petersen CS. Efficacy and safety of tacrolimus ointment compared with hydrocortisone treatment in odults with moderote to severe atopic dermatitis. J Eur Acad Dermatol Venereol 2002; 16(Suppl. 1): 4 (Abstract S2 - 3).
25. Luger T, van Leent EJ, Groeber M, Hedgecock S, Thurston M, Kandra A, et al. SDZ ASM 981: an emerging safe and effective treatment for otopic dermatitis. Br J Dermatol 2001; 144: 788-94.
26. Reitamo S, Remitz A, Kyllonen H, Saarikko J, Granlund H. Topical noncorticosteroid immunomodulation in the treatment of atopic dermotitis. Am J Clin Dermotol 2002; 3: 381-8.
27. Soter NA, Fleischer AB Jr., Webster GF, Monroe E, Lowrence I. Tacrolimus ointment for the treatment of atopic dermotitis in adult potients: part II, safety. J Am Acad Dermatol 2001; 44(Suppl. 1): S39-46.
28. Poller A, Eichenfield LF, Leung DY, Stewort D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediotric patients. J Am Acod Dermotol 2001; 44(Suppl. 1): S47-57.
29. Hanifin J, Ho V, Kaufann R, Kapp A, Honig P, Koo J, et al. Pimecrolimus (SDZ ASM 981) creom: good tolerability in pediatric patients. Ann Dermatal Vener 2002; 129 supp 1: S411.
30. Scheuplein RJ, Blank IH. Permeability of the skin. Physiol Rev 1971; 51: 702-47.
31. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9: 165-9.
32. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998; 38: 69-76.
33. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144: 781-7.
34. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102: 555-7.
35. Billich A, Aschauer H, Stuetz A. Pimecrolimus (SDZ ASM 981) is more lipophilic and permeates less through skin than tacrolimus (FK506). Ann Dermatol Vener 2002; 129 supp 1 : S682-3.
36. Billich A, Aschauer H, Stuetz A. Pimecrolimus (SDZ ASM 981) permeates less through skin thon topical corticosteroids. Ann Dermatol Vener 2002; 129 supp 1: S693.
37. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-41.
38. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug far the turn of the millennium ? Arch Dermatol 1999; 135: 574-80.
39. Schweitzer A, Figueiredo J, Zehender H, Grassberger M. Pimecrolimus (SDZ ASM 981) has high affinity for skin - a tissue distribution study in rats in comparison with tacrolimus (FK506). Ann Dermatol Vener 2002; 129 supp 1: S704.
40. Undre NA, Green A, Harper J, Rubins A, Zigure S, Bourke J, et al. Tacrolimus pharmacokinetics in paediatric patients with moderate to severe atopic dermatitis after single and repeated application. Ann Dermatol Vener 2002; 129 supp 1: S424.
41. Undre NA, Rubins A, Gutmane R, Valdmane N, Stevenson P. Pharmacokinetics of tacrolimus ointment in adult patients with moderate to severe atopic dermatitis. Ann Dermatol Vener 2002; 129 supp 1: S425.
42. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated tapical application of pimecrolimus (Elidel), SDZ ASM 981, in patients with atopic dermatitis. Dermatol 2002; 204: 63-8.
43. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, et al. For the European Tacralimus Ointment Study Group. Sofety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006.
44. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD, et al. For the European Tacrolimus Multicenter Atopic Dermatitis Study Group. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21.
45. Lakhanpaul M, Davies T, Allen B, Stephenson T, Scott G, Ebelin M-E. Pimecrolimus (SDZ ASM 981) cream 1%: minimal systemic absorption in infants with atopic dermatitis during long-term treatment. Ann Dermatol Vener 2002; 129 supp 1: S415.
46. Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treotment of atopic dermatitis. Arch Dermatol 1998; 134: 805-9.
47. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DY, Hanifin JM, for the Pediatric Tacrolimus Study Group. A randomized, vehicle-controlled trial of tocrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44.
48. Allen A, Siegfried E, Silverman R, Williams M, Elias P, Szabo S, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermotol 2001; 137: 747-50.
49. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002; 14: 414-8.
50. Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthmo Proc 2002; 23: 191-7.
51. Kang S, Lucky AW, Pariser D, Lowrence I, Honifin JM. Long-term safety ond efficacy of tacrolimus ointment for the treatment of otopic dermotitis in children. J Am Acad Dermatol 2001; 44(Suppl. 1): S58-64.
52. Koo J, Prose N, Fleischer A, Rico MJ. Safety ond efficacy of tacrolimus ointment monotherapy in over 7,900 atopic dermatitis patients: results of an open-label study. Ann Dermatol Vener 2002; 129 supp 1: S414-5.
53. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
54. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504.
55. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter P, et al. Pimecrolimus (SDZ ASM 981) cream: a new treatment strategy for the long-term management of atopic dermatitis in infants. Ann Dermatol Vener 2002; 129 supp 1: S412. 20th World Congress in Dermatology, Paris, France, 1-5 July 2002: Poster presentation P214.
56. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter P, et al. Pimecrolimus (SDZ ASM 981) cream: a new treatment strategy for the long-term management of atopic dermatitis in infants. Ann Dermatol Vener 2002; 129 supp 1: S412. 20th World Congress in Dermatology, Paris, France, 1-5 July 2002: Poster presentation P214.
57. Fleischer AB Jr., Ling M, Eichenfield L, Satoi Y, Jaracz E, Rico MJ, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70.